Fig. 6: Inhibition of c-MET reverses anoikis resistance induced by BRN2 expression.
From: BRN2 expression increases anoikis resistance in melanoma
a–c Cellular viability counts following 7 days growth under ultra-low-adherence conditions either with or without induction of expression of BRN2 or lacZ as a control with or without inhibition of c-MET with 0.25 µm crizotinib (CRIZ). a MM370 cells, b MM455 cells, c MM603 cells. d, e MM370 cellular viability counts following 7 days under the above conditions with or without inhibition of c-MET with d 0.25 µm foretinib (FORE) or e 1.25 nm capmatinib (CAP). a–c Values indicate mean ± SEM, n = at least duplicate counts from three independent experiments. d, e Values indicate mean ± SEM, n = triplicate counts from two independent experiments. *p < 0.05, **p < 0.01, ****p < 0.0001; unpaired t test.
